Oliceridine and its potential to revolutionize GI endoscopy sedation

Providing sedation to patients undergoing gastrointestinal (GI) endoscopy is a controversial and emotive issue. The mainstay of sedation is propofol, whose administration is within the sole jurisdiction of anesthesia providers, at least in the USA. Attempts have been made to seize the authority by t...

Full description

Bibliographic Details
Main Authors: Basavana Goudra, Preet Mohinder Singh
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Saudi Journal of Anaesthesia
Subjects:
Online Access:http://www.saudija.org/article.asp?issn=1658-354X;year=2020;volume=14;issue=3;spage=349;epage=354;aulast=Goudra
_version_ 1828343043160276992
author Basavana Goudra
Preet Mohinder Singh
author_facet Basavana Goudra
Preet Mohinder Singh
author_sort Basavana Goudra
collection DOAJ
description Providing sedation to patients undergoing gastrointestinal (GI) endoscopy is a controversial and emotive issue. The mainstay of sedation is propofol, whose administration is within the sole jurisdiction of anesthesia providers, at least in the USA. Attempts have been made to seize the authority by the GI community. One of the first attempts was the use of the prodrug of propofol –fospropofol. However, as the drug has a similar adverse effect profile as propofol in terms of respiratory depression, the FDA did not approve its use by providers other than those trained in airway management. Sedasys® was the next attempt, which was a computer-assisted personalized sedation system. As a result of insufficient sedation that could be provided with the device, although very successful in research settings, it was not a commercial success. It seems that remimazolam is the next effort in this direction. It is likely to fail in this regard unless its respiratory depressant properties and failure rates could be addressed. G protein-biased μ-receptor agonists are a new class of opioids exhibiting analgesic properties similar to morphine without equivalent respiratory depressant properties. Oliceridine is the prototype. As a result, the drug can be additive to midazolam or remimazolam and allow screening colonoscopy to be comfortably completed without the need for propofol. For an anesthesia provider, the administration of oliceridine can eliminate the need for drugs such as fentanyl that add to the respiratory depressant properties of propofol. As a result, oliceridine has the potential to render the sedation for GI endoscopy procedures both safe and cost-effective.
first_indexed 2024-04-13T23:37:06Z
format Article
id doaj.art-6a37f2110bb244f5946d600027e05ca9
institution Directory Open Access Journal
issn 1658-354X
language English
last_indexed 2024-04-13T23:37:06Z
publishDate 2020-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Saudi Journal of Anaesthesia
spelling doaj.art-6a37f2110bb244f5946d600027e05ca92022-12-22T02:24:41ZengWolters Kluwer Medknow PublicationsSaudi Journal of Anaesthesia1658-354X2020-01-0114334935410.4103/sja.SJA_813_19Oliceridine and its potential to revolutionize GI endoscopy sedationBasavana GoudraPreet Mohinder SinghProviding sedation to patients undergoing gastrointestinal (GI) endoscopy is a controversial and emotive issue. The mainstay of sedation is propofol, whose administration is within the sole jurisdiction of anesthesia providers, at least in the USA. Attempts have been made to seize the authority by the GI community. One of the first attempts was the use of the prodrug of propofol –fospropofol. However, as the drug has a similar adverse effect profile as propofol in terms of respiratory depression, the FDA did not approve its use by providers other than those trained in airway management. Sedasys® was the next attempt, which was a computer-assisted personalized sedation system. As a result of insufficient sedation that could be provided with the device, although very successful in research settings, it was not a commercial success. It seems that remimazolam is the next effort in this direction. It is likely to fail in this regard unless its respiratory depressant properties and failure rates could be addressed. G protein-biased μ-receptor agonists are a new class of opioids exhibiting analgesic properties similar to morphine without equivalent respiratory depressant properties. Oliceridine is the prototype. As a result, the drug can be additive to midazolam or remimazolam and allow screening colonoscopy to be comfortably completed without the need for propofol. For an anesthesia provider, the administration of oliceridine can eliminate the need for drugs such as fentanyl that add to the respiratory depressant properties of propofol. As a result, oliceridine has the potential to render the sedation for GI endoscopy procedures both safe and cost-effective.http://www.saudija.org/article.asp?issn=1658-354X;year=2020;volume=14;issue=3;spage=349;epage=354;aulast=Goudraendoscopy; oliceridine; propofol; remimazolam; sedation
spellingShingle Basavana Goudra
Preet Mohinder Singh
Oliceridine and its potential to revolutionize GI endoscopy sedation
Saudi Journal of Anaesthesia
endoscopy; oliceridine; propofol; remimazolam; sedation
title Oliceridine and its potential to revolutionize GI endoscopy sedation
title_full Oliceridine and its potential to revolutionize GI endoscopy sedation
title_fullStr Oliceridine and its potential to revolutionize GI endoscopy sedation
title_full_unstemmed Oliceridine and its potential to revolutionize GI endoscopy sedation
title_short Oliceridine and its potential to revolutionize GI endoscopy sedation
title_sort oliceridine and its potential to revolutionize gi endoscopy sedation
topic endoscopy; oliceridine; propofol; remimazolam; sedation
url http://www.saudija.org/article.asp?issn=1658-354X;year=2020;volume=14;issue=3;spage=349;epage=354;aulast=Goudra
work_keys_str_mv AT basavanagoudra oliceridineanditspotentialtorevolutionizegiendoscopysedation
AT preetmohindersingh oliceridineanditspotentialtorevolutionizegiendoscopysedation